Salarius Pharmaceuticals (NASDAQ:SLRX) Issues Quarterly Earnings Results

Salarius Pharmaceuticals (NASDAQ:SLRX) issued its quarterly earnings data on Friday. The company reported ($0.66) earnings per share for the quarter, Zacks reports.

Salarius Pharmaceuticals Stock Performance

Shares of SLRX opened at $0.95 on Friday. The company has a market cap of $1.65 million, a price-to-earnings ratio of -0.12 and a beta of 0.59. The stock has a fifty day moving average price of $1.72 and a two-hundred day moving average price of $1.61. Salarius Pharmaceuticals has a 52-week low of $0.83 and a 52-week high of $7.20.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.